Neurology:噻吩并吡啶筛选适合 PFO 封堵术的偏头痛患者

2018-12-17 杨中华 脑血管病及重症文献导读

非盲法观察性研究显示卵圆孔(PFO)封堵术能够显著降低偏头痛(migraine headache,MHA)的频率,提示 PFO 可能是 MHA 的病因。但是截止到目前为止,PFO 或右向左分流触发 MHA 的病理生理机制尚不清楚。此外,我们尚无法把 MHA 相关性 PFO 从那些偶然发现的 PFO 区分开来,这可能也是为什么以前的 PFO/MHA 试验失败的原因。


非盲法观察性研究显示卵圆孔(PFO)封堵术能够显著降低偏头痛(migraine headache,MHA)的频率,提示 PFO 可能是 MHA 的病因。但是截止到目前为止,PFO 或右向左分流触发 MHA 的病理生理机制尚不清楚。此外,我们尚无法把 MHA 相关性 PFO 从那些偶然发现的 PFO 区分开来,这可能也是为什么以前的 PFO/MHA 试验失败的原因。

我们使用氯吡格雷(P2Y2受体抑制剂)治疗过一些阿司匹林过敏的缺血性卒中/PFO患者,以减少卒中复发的风险,但是未料到却发现氯吡格雷能够减少 MHA 的症状。这些经验促使我们采用氯吡格雷治疗了一小部分非卒中的偏头痛患者。15个患者中13个患者的 MHA 症状减少,提示MHA 和 PFO 之间的关系是与血小板有关,这符合CANOA 试验的结果,因为该试验发现服用氯吡格雷联合阿司匹林患者的 MHA 症状比单独服用阿司匹林者更少。

2018年11月来自美国的Robert J. Sommer等在 Neurology 上公布了他们的研究结果,探讨噻吩并吡啶在 MHA 合并 PFO 患者的作用。

从2011年到2017年,MHA 合并 PFO 的患者给予氯吡格雷治疗 MHA。MHA 反应者定义为每月 MHA 的天数比基线降低>50%。MHA 无反应者如果 PRU 检测发现血小板抑制率不充分者给予普拉格雷治疗。噻吩并吡啶反应者给予 PFO 封堵术。

共136例患者(女性86%,平均年龄37.9岁,MHA 负荷为14.7天/月),80例(59%)为氯吡格雷反应者。在发作性、慢性、先兆和非先兆亚组中,氯吡格雷反应者的比例相同。19/45(40%)MHA 无反应者的血小板抑制不足(采用 PRU 检测氯吡格雷)。普拉格雷治疗的16例患者的血小板抑制充分(PRU 检测),其中10例(10/16,62%)变为 MHA 反应者。总共56/90例噻吩并吡啶反应者随后进行了 PFO 封堵术,3个月后停用噻吩并吡啶。94%的 MHA 得到缓解。8/8例反应者停用了噻吩并吡啶并且未进行 PFO,重新出现了 MHA 症状。

最终作者认为,充分P2Y12血小板抑制似乎能够减少合并 PFO 患者的 MHA 症状,提示 MHA 可能与血小板有关。PFO 封堵术近乎100%的有效性,提示静脉血小板激活联合 PFO 右向左分流可能是 MHA 的发病机制。以后进行 MHA/PFO相关试验时,可以采用噻吩并吡啶反应性筛选适合入选的患者。

原始出处:

Robert J. Sommer,et al.Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale.Neurology. 2018 Nov 27;91(22):1002-1009. doi: 10.1212/WNL.0000000000006572.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924757, encodeId=286a1924e570a, content=<a href='/topic/show?id=f9dc1412453' target=_blank style='color:#2F92EE;'>#PFO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14124, encryptionId=f9dc1412453, topicName=PFO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sat Nov 09 13:42:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060998, encodeId=510a2060998e8, content=<a href='/topic/show?id=e70046e74d3' target=_blank style='color:#2F92EE;'>#封堵术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46774, encryptionId=e70046e74d3, topicName=封堵术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 01 21:42:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000661, encodeId=f41020006615d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Feb 06 11:42:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584413, encodeId=5e831584413df, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Dec 19 11:42:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-11-09 Boyinsh
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924757, encodeId=286a1924e570a, content=<a href='/topic/show?id=f9dc1412453' target=_blank style='color:#2F92EE;'>#PFO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14124, encryptionId=f9dc1412453, topicName=PFO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sat Nov 09 13:42:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060998, encodeId=510a2060998e8, content=<a href='/topic/show?id=e70046e74d3' target=_blank style='color:#2F92EE;'>#封堵术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46774, encryptionId=e70046e74d3, topicName=封堵术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 01 21:42:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000661, encodeId=f41020006615d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Feb 06 11:42:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584413, encodeId=5e831584413df, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Dec 19 11:42:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-04-01 ycmayy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924757, encodeId=286a1924e570a, content=<a href='/topic/show?id=f9dc1412453' target=_blank style='color:#2F92EE;'>#PFO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14124, encryptionId=f9dc1412453, topicName=PFO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sat Nov 09 13:42:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060998, encodeId=510a2060998e8, content=<a href='/topic/show?id=e70046e74d3' target=_blank style='color:#2F92EE;'>#封堵术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46774, encryptionId=e70046e74d3, topicName=封堵术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 01 21:42:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000661, encodeId=f41020006615d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Feb 06 11:42:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584413, encodeId=5e831584413df, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Dec 19 11:42:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-02-06 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924757, encodeId=286a1924e570a, content=<a href='/topic/show?id=f9dc1412453' target=_blank style='color:#2F92EE;'>#PFO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14124, encryptionId=f9dc1412453, topicName=PFO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sat Nov 09 13:42:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060998, encodeId=510a2060998e8, content=<a href='/topic/show?id=e70046e74d3' target=_blank style='color:#2F92EE;'>#封堵术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46774, encryptionId=e70046e74d3, topicName=封堵术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 01 21:42:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000661, encodeId=f41020006615d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Feb 06 11:42:00 CST 2019, time=2019-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584413, encodeId=5e831584413df, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Dec 19 11:42:00 CST 2018, time=2018-12-19, status=1, ipAttribution=)]

相关资讯

JAMA:PCI术后1年,还需要继续双抗血小板治疗吗?

经皮冠状动脉介入术(PCI)后进行双重抗血小板治疗可减少缺血性风险,但会增加出血风险。研究者进行了一项试验,建立一个临床决策工具,以识别PCI术后1年持续使用噻吩并吡啶类抗血小板药物的优劣。该研究纳入了11个国家的11 648名患者(DAPT 研究),根据PCI术后12-30个月的缺血和出血风险建立预测规则,再经过8136名患者进行验证(PROTECT)。先进行长达12个月的噻吩并吡啶+阿司匹林治

Stroke:PPI与噻吩并吡啶

关于PPI和噻吩并吡啶交互作用的大部分研究多聚焦心血管事件,仅几项研究报道了脑血管事件。个别研究未能确定氯吡格雷联合PPI对缺血性卒中的影响。此外,由于缺乏证据(矛盾的结果),缺乏一致性意见,PPI联合噻吩并吡啶啶啶是临床的一道谜题。